[How far the rates of cholesterol have to be lowered in primary prevention?].
Rodondi
Nicolas
N
D000328:Adult; D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use; D001384:Azetidines / Q000191:economics / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D018849:Controlled Clinical Trials as Topic / Q000191:economics; D003362:Cost-Benefit Analysis; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000627:therapeutic use; D011322:Primary Prevention; D012307:Risk Factors; D019821:Simvastatin / Q000191:economics / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol; D019821:Simvastatin; D000069438:Ezetimibe